RPS30A Antibody

What is RPS3A and what cellular functions does it perform?

RPS3A (40S ribosomal protein S3a) is a component of the small ribosomal subunit. It functions as part of the large ribonucleoprotein complex responsible for protein synthesis in cells . Beyond its canonical role in translation, RPS3A is specifically involved in the small subunit (SSU) processome, which is the first precursor of the small eukaryotic ribosomal subunit. During SSU processome assembly in the nucleolus, RPS3A works alongside other ribosome biogenesis factors and RNA chaperones to generate RNA folding, modifications, rearrangements, and cleavage, as well as targeted degradation of pre-ribosomal RNA by the RNA exosome . RPS3A may also play a role during erythropoiesis through regulation of transcription factor DDIT3, though this function has been primarily observed through similarity studies rather than direct evidence .

How does RPS3A differ from other ribosomal proteins like RPSA?

While RPS3A (Ribosomal Protein S3A) and RPSA (Ribosomal Protein SA) are both components of the small ribosomal subunit, they have distinct functions and are encoded by different genes. RPS3A is primarily involved in ribosome assembly and protein synthesis , while RPSA has dual functionality - it's required for the assembly and stability of the 40S ribosomal subunit and also functions as a cell surface receptor for laminin . RPSA plays roles in cell adhesion to the basement membrane and subsequent activation of signaling transduction pathways, potentially influencing cell fate determination and tissue morphogenesis . In terms of associated pathologies, RPSA is linked to conditions like Asplenia and Venezuelan Equine Encephalitis , while RPS3A has been implicated in various cancers, particularly hepatocellular carcinoma .

What experimental techniques are compatible with RPS3A antibodies?

RPS3A antibodies are versatile tools compatible with multiple experimental techniques used in molecular and cellular biology research. Based on available data, RPS3A antibodies like the rabbit polyclonal ab264368 from Abcam have been validated for several key applications :

• Western Blotting (WB): For detecting RPS3A protein levels in cell and tissue lysates, with successful detection in human and mouse samples.

• Immunohistochemistry on paraffin-embedded sections (IHC-P): For visualizing RPS3A localization and expression in tissue sections.

• Immunoprecipitation (IP): For isolating RPS3A and its binding partners from complex protein mixtures.

Additionally, research studies have successfully employed RPS3A antibodies in techniques such as:

• Immunohistochemistry (IHC) staining for correlation analyses with immune cell infiltration in tumor samples

• Protein detection following extraction with RIPA buffer supplemented with protease and phosphatase inhibitors

These applications make RPS3A antibodies valuable tools for studying both expression patterns and functional roles of this protein in various biological contexts.

How can I validate the specificity of my RPS3A antibody?

Validating the specificity of RPS3A antibodies is crucial for generating reliable experimental results. A comprehensive validation approach should include multiple complementary methods:

• Western blot analysis: Use positive controls (cells/tissues known to express RPS3A) and negative controls (where possible). The antibody should detect a band at the expected molecular weight for RPS3A. For instance, when analyzing HCC cell lines versus normal hepatocytes (L-02), a stronger signal should be observed in HCC cells, which express higher RPS3A levels .

• Immunohistochemistry controls: Compare staining between tissues with different expression levels. Research has shown significantly higher percentages of moderate (28.57%) and strong (22.73%) staining of RPS3A in HCC samples compared to adjacent tumor-free tissue samples .

• Correlation with mRNA expression: Verify that protein detection correlates with mRNA levels as measured by qRT-PCR. Using primers like RPS3A-forward: 5'-CGAGAGGTGCAGACAAATGA-3' and RPS3A-reverse: 5'-CGAAGACATCATGGAGAGGATAAA-3' can help confirm that the detected protein correlates with gene expression .

• Knockdown or knockout validation: If possible, test the antibody in systems where RPS3A has been silenced or knocked out to confirm the specificity of detection.

• Cross-reactivity assessment: Test the antibody against closely related proteins (like other ribosomal proteins) to ensure it doesn't cross-react with similar epitopes.

Following these validation steps will ensure that experimental observations truly reflect RPS3A biology rather than non-specific antibody interactions.

How does RPS3A expression correlate with immune cell infiltration in tumors?

RPS3A expression has a significant negative correlation with tumor immune cell infiltration, as demonstrated by both bioinformatic analyses and experimental validation. Using single-sample gene set enrichment analysis (ssGSEA) on transcriptome profiling data from 356 HCC patients in the TCGA database, researchers discovered that high RPS3A expression is strongly associated with low infiltration of several immune cell types .

The strongest negative correlations were observed with:

• Th17 cells (r = -0.42, P < 0.001)

• Neutrophils (r = -0.3, P < 0.001)

• Dendritic cells (r = -0.24, P < 0.001)

Immunohistochemistry studies further confirmed this relationship, particularly with CD8+ cytotoxic T lymphocytes (CTLs), which are crucial for anti-tumor immunity. About 65% (49 of 75) of tumors with low RPS3A expression showed high CD8+ CTL infiltration, while approximately 63% (50 of 79) of tumors with high RPS3A expression exhibited negative or weak CD8+ staining .

These findings suggest that RPS3A may contribute to tumor immune evasion mechanisms, potentially explaining why high RPS3A expression correlates with poorer clinical outcomes in HCC patients.

What is the relationship between RPS3A and immune checkpoint molecules?

Research has revealed a striking positive correlation between RPS3A expression and various immune checkpoint molecules in HCC. PCR array analyses demonstrated distinct transcriptional profiles of immune checkpoint molecules between HCC patients with high versus low RPS3A mRNA expression . Specifically, correlation analyses showed significant positive associations between RPS3A expression and multiple immune checkpoint molecules including:

These strong positive correlations suggest a direct pathogenic link between RPS3A expression and induced tumor immune evasion . This relationship may explain why tumors with high RPS3A expression exhibit lower immune cell infiltration and poorer clinical outcomes. Additionally, these findings suggest that RPS3A could potentially serve as a predictive biomarker for response to immune checkpoint blockade therapy in HCC patients.

What experimental approach is optimal for studying RPS3A's role in cancer immunotherapy resistance?

To comprehensively investigate RPS3A's role in cancer immunotherapy resistance, a multi-faceted experimental approach is recommended:

• Patient cohort analyses: Compare RPS3A expression levels in responders versus non-responders to immune checkpoint blockade therapy using:

  • Immunohistochemistry for protein expression

  • qRT-PCR for mRNA quantification (using validated primers such as RPS3A-forward: 5'-CGAGAGGTGCAGACAAATGA-3' and RPS3A-reverse: 5'-CGAAGACATCATGGAGAGGATAAA-3')

  • RPS3A-based nomograms to predict therapy response

• Mechanistic studies:

  • RPS3A manipulation in cancer cells through knockdown/overexpression experiments

  • Co-culture systems with immune cells to assess direct effects on immune cell function

  • RNA-seq and proteomics to identify pathways affected by RPS3A modulation

• Animal models:

  • Generate RPS3A-modulated tumor xenografts in immunocompetent models

  • Test response to various immunotherapies

  • Analyze tumor immune infiltration using flow cytometry and multiplexed IHC

• Checkpoint molecule assessment:

  • Use PCR arrays to profile immune checkpoint molecule expression patterns before and after RPS3A modulation

  • Validate findings at protein level through Western blotting and flow cytometry

• Combination therapy testing:

  • Assess whether RPS3A inhibition sensitizes resistant tumors to immune checkpoint blockade

  • Test various sequencing approaches (concurrent vs. sequential therapy)

This comprehensive approach would provide both correlative and causative evidence for RPS3A's role in immunotherapy resistance while potentially identifying therapeutic strategies to overcome such resistance.

What are the optimal conditions for using RPS3A antibodies in Western blotting?

For optimal Western blotting results with RPS3A antibodies, researchers should follow these methodological considerations:

• Sample preparation:

  • Lyse cells in RIPA extraction reagent supplemented with protease inhibitors (e.g., from Roche) and phosphatase inhibitors (e.g., from Sigma-Aldrich)

  • Load approximately 20 μg of protein per well for standard detection

  • Use appropriate positive controls (HCC cell lines express high levels of RPS3A) and negative controls (normal hepatocytes like L-02 express lower levels)

• Gel electrophoresis:

  • 10% polyacrylamide gels have been successfully used for RPS3A separation

  • Include molecular weight markers to verify the expected size of RPS3A

• Transfer and blocking:

  • Transfer to appropriate membranes (e.g., PVDF or nitrocellulose from Millipore)

  • Block with 5% nonfat dry milk to minimize background

• Antibody incubation:

  • Primary antibody: Anti-RPS3A at 1:1000 dilution (e.g., from Abcam)

  • Loading control: Anti-GAPDH at 1:1000 dilution (e.g., from Sigma-Aldrich)

  • Secondary antibody: 1:5000 dilution (e.g., from Jackson ImmunoResearch Laboratories)

• Detection:

  • Use chemiluminescent imaging systems (e.g., Tanon-5200 Chemiluminescent Imaging System)

  • Exposure time may need optimization based on expression levels

By following these optimized conditions, researchers can achieve specific and sensitive detection of RPS3A protein in their experimental systems.

How can I quantitatively assess RPS3A mRNA expression in tissue samples?

Quantitative assessment of RPS3A mRNA expression in tissue samples requires careful methodology to ensure accurate and reproducible results. Based on published research, the following optimized protocol is recommended:

• RNA extraction:

  • For cell lines: Extract total RNA using TRIzol reagent (Invitrogen)

  • For tissue samples: Immerse tissues in TRIzol (Invitrogen) immediately after collection

  • Ensure RNA quality by checking RNA integrity number (RIN) values

• cDNA synthesis:

  • Use a reliable reverse transcription kit such as PrimeScript RT reagent kit (Takara Bio)

  • Standardize the amount of input RNA (typically 0.5-1 μg for good sensitivity)

• qRT-PCR setup:

  • Instrument: ABI Prism 7500 Sequence Detection system (Applied Biosystems) or equivalent platform

  • Chemistry: SYBR Premix ExTaq (Takara Bio) or similar SYBR-based system

  • Validated primers:

    • RPS3A-forward: 5'-CGAGAGGTGCAGACAAATGA-3'

    • RPS3A-reverse: 5'-CGAAGACATCATGGAGAGGATAAA-3'

  • Reference gene primers:

    • β-actin-forward: 5'-GGACCTGACTGACTACCTCAT-3'

    • β-actin-reverse: 5'-CGTAGCACAGCTTCTCCTTAAT-3'

• Data analysis:

  • Use the 2^(-ΔΔCT) method for relative quantification

  • For comparison between groups, normalize to appropriate reference genes

  • Include appropriate statistical analyses (e.g., t-tests for two-group comparisons)

• Advanced applications:

  • For simultaneous analysis of RPS3A and immune checkpoint molecules, consider using a PCR array system like RT^2 Profiler PCR Array (BioTNT)

  • For such arrays, follow manufacturer-specific protocols for normalization using housekeeping genes

This methodological approach has been successfully implemented in research examining RPS3A expression in HCC and its correlation with immune checkpoint molecules .

What are the technical challenges in studying RPS3A's interactions with the immune microenvironment?

Studying RPS3A's interactions with the immune microenvironment presents several technical challenges that researchers should consider when designing experiments:

• Complexity of the tumor immune microenvironment:

  • Multiple immune cell types with distinct functions and markers must be simultaneously assessed

  • Solution: Use comprehensive approaches like single-sample gene set enrichment analysis (ssGSEA) to evaluate multiple immune cell types combined with validation through multiplexed immunohistochemistry

• Causality versus correlation:

  • Determining whether RPS3A directly influences immune cell infiltration or if both are affected by another factor

  • Solution: Design mechanistic studies with RPS3A manipulation (overexpression/knockdown) followed by immune profiling

• Tissue heterogeneity:

  • Tumor samples contain varying proportions of cancer cells, stromal cells, and immune cells

  • Solution: Consider laser-capture microdissection or single-cell approaches to address heterogeneity

• Dynamic nature of immune responses:

  • Immune infiltration changes over time and disease progression

  • Solution: Use longitudinal sampling when possible and correlate with disease stage

• Technical variability in antibody-based detection:

  • Different antibody clones and detection protocols may yield varying results

  • Solution: Validate findings with multiple antibodies and complementary techniques (e.g., flow cytometry, IHC, and RNA-seq)

• Integration of protein and transcriptomic data:

  • Correlating RPS3A protein levels (by IHC) with immune cell transcriptomic signatures

  • Solution: Use matched samples for both analyses and appropriate statistical methods for integration

• In vivo modeling limitations:

  • Animal models may not fully recapitulate human immune responses

  • Solution: Consider humanized mouse models for more translational relevance

By anticipating these challenges and implementing appropriate strategies, researchers can more effectively investigate the complex interplay between RPS3A and the tumor immune microenvironment.

How might RPS3A serve as a predictive biomarker for immunotherapy response?

RPS3A shows significant potential as a predictive biomarker for immunotherapy response, particularly for immune checkpoint blockade (ICB) therapy in hepatocellular carcinoma. This potential is supported by several key findings:

• Strong correlation with immune infiltration: The negative correlation between RPS3A expression and tumor immune cell infiltration, particularly CD8+ T cells, suggests that high RPS3A expression may identify tumors with an "immune-cold" phenotype that typically responds poorly to immunotherapy .

• Association with immune checkpoint molecules: RPS3A expression strongly correlates with multiple immune checkpoint molecules including CTLA4 (r = 0.95), PDCD1/PD-1 (r = 0.93), and TIGIT (r = 0.95) . This suggests that RPS3A may be involved in or indicative of active immune suppression mechanisms that could influence response to various checkpoint inhibitors.

• Prognostic value: RPS3A-based nomograms have demonstrated better predictive accuracy for HCC prognosis compared to traditional staging systems . This prognostic power could potentially extend to therapy response prediction.

To develop RPS3A as a clinical biomarker, future research should:

• Conduct retrospective analyses of RPS3A expression in samples from immunotherapy clinical trials

• Develop standardized IHC or qPCR protocols for clinical RPS3A assessment

• Determine optimal cut-off values for "high" versus "low" expression

• Investigate whether combining RPS3A with other biomarkers (e.g., PD-L1 expression, tumor mutational burden) improves predictive power

• Validate findings across multiple cancer types and immunotherapy regimens

Such research could ultimately lead to the incorporation of RPS3A testing into clinical decision-making for immunotherapy administration, potentially sparing patients from ineffective treatments while directing them to more promising alternatives.

What is the potential for developing therapeutic strategies targeting RPS3A?

The emerging understanding of RPS3A's role in cancer progression and immune evasion suggests several potential therapeutic strategies targeting this protein:

• Direct RPS3A inhibition:

  • Small molecule inhibitors disrupting RPS3A's ribosomal functions

  • Antisense oligonucleotides or siRNA approaches to reduce RPS3A expression

  • Targeted protein degradation strategies (e.g., PROTACs) specific to RPS3A

• Combinatorial approaches with immunotherapy:

  • RPS3A inhibition could potentially convert "immune-cold" tumors to "immune-hot" tumors by enhancing immune cell infiltration

  • Sequential treatment with RPS3A inhibitors followed by immune checkpoint inhibitors may improve response rates

  • Dual targeting of RPS3A and specific immune checkpoint molecules (e.g., CTLA4, PD-1) that show strong correlation with RPS3A expression

• Cancer-specific delivery strategies:

  • Since normal cells also require RPS3A for protein synthesis, cancer-specific delivery systems would be crucial

  • Tumor-targeting nanoparticles or antibody-drug conjugates could help achieve cancer-selective effects

  • Exploiting differential dependence on RPS3A between normal and cancer cells

• Targeting downstream effectors:

  • Identify and target the key downstream pathways through which RPS3A mediates immune suppression

  • Gene set enrichment analysis (GSEA) has suggested that high RPS3A expression promotes biological processes related to tumorigenesis, metastasis, and immunosuppression

Challenges to overcome include:

• Potential toxicity due to RPS3A's essential role in protein synthesis

• Identifying the precise mechanisms by which RPS3A influences the tumor immune microenvironment

• Determining optimal dosing and scheduling for combination therapies

The strong negative correlation between RPS3A expression and tumor immune cell infiltration, coupled with its association with poor prognosis, makes it a promising therapeutic target, particularly for enhancing immunotherapy efficacy in cancers like HCC.

What are the most critical considerations when interpreting RPS3A antibody experimental results?

• Antibody specificity and validation: Ensure the antibody has been properly validated for the specific application and species being studied. Different antibodies may recognize different epitopes of RPS3A, potentially affecting detection of specific forms or conformations of the protein .

• Biological context: RPS3A functions within complex networks involving ribosome biogenesis, protein synthesis, and potentially immune regulation. Results should be interpreted in the context of these multiple functions rather than in isolation .

• Expression heterogeneity: RPS3A expression can vary significantly across different cell types and pathological states. For instance, in HCC studies, RPS3A expression showed distinct patterns in cancer versus adjacent normal tissue . Consider whether observed variations represent true biological differences or technical artifacts.

• Correlation versus causation: While correlations between RPS3A expression and phenomena like immune cell infiltration are compelling, they don't necessarily indicate direct causation . Mechanistic studies are needed to establish causal relationships.

• Technical considerations: Variables such as tissue fixation methods for IHC, protein extraction protocols for Western blotting, and normalization methods for qPCR can all influence results and should be carefully controlled and reported .

• Therapeutic implications: When considering RPS3A as a therapeutic target or biomarker, account for both its canonical ribosomal functions and non-canonical roles, as disrupting essential cellular processes may lead to unintended consequences.

What consensus findings have emerged from RPS3A research and what questions remain unresolved?

Research on RPS3A has yielded several consensus findings while leaving important questions unresolved, creating opportunities for future investigation.

Consensus Findings:

Unresolved Questions:

• What are the specific molecular mechanisms by which RPS3A influences immune cell infiltration and function within the tumor microenvironment?

• Does RPS3A have direct non-ribosomal functions that contribute to tumor progression and immune evasion, or are these effects secondary to its role in translation?

• How does RPS3A expression change during cancer progression and in response to various therapies, particularly immunotherapies?

• Can RPS3A be effectively targeted therapeutically without disrupting essential cellular processes in normal cells?

• Does the relationship between RPS3A and immune function observed in HCC extend to other cancer types?

• What is the functional significance of the strong correlation between RPS3A and immune checkpoint molecules?

• How do post-translational modifications affect RPS3A's various functions?